AiCuris Anti-infective Cures GmbH
AiCuris is a pharmaceutical company focused on discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially lifethreatening infectious diseases. Since November 2017, the first product from AiCuris is on the market. Letermovir, designed to inhibit the viral terminase of the human cytomega-lovirus (CMV) and licensed to MSD and achieved market approval in the US, Europe and Japan for the prophylaxis of CMV infections in recipients of bone marrow transplants.
Further clinical programs include Pritelivir, a helicase-primase inhibitor, developed to treat recurrent labial herpes and genital herpes infections, AIC499, a resistancebreaking Gram(-) antibiotic and AIC649, an immune modulator targeted at Hepatitis B cure.
AiCuris at a glance:
| Field of Activity | Anti-infectives including antivirals (HCMV, HSV, Hepatitis B virus, Adenovirus) and antibacterials (hospital infections caused by multiresistant Gram-(-) and Gram-(+) bacteria). |
| Ownership Structure and Financing | Private investors, led by the family office of the Dres. Strüngmann, former owners of Hexal. |
| Partners | Merck & Co. (MSD): Licensee of AiCuris‘ HCMV drug Letermovir, MPI Institute of Molecular Physiology, Institut Català d’Investigació Quimica, Mercachem, Cyclenium, Lysando AG Innovative Medicines Initiative (IMI) AiCuris intends to move its projects to clinical proof-of-concept before licensing/partnering. AiCuris pursues an active in-licensing strategy for pre-clinical and early clinical projects. |
| Products / Services | AiCuris‘ Clinical Programs: Letermovir, (licensed to MSD), HCMV, Marketed (HSCT), Ph 3 (SOT) Pritelivir, HSV resistant, Phase 2 /HSV vaginal ring, Preclinical AIC649, Hepatitis B Virus, Phase 1 Artilysins, against bacteria, Preclinical Research |
| Unique Selling Point | AiCuris‘ innovative antibiotic and antiviral drugs act via new modes of action and are directed against new targets and/or represent novel chemical classes. Based on this, AiCuris‘ therapeutics are resistance-breaking by design. |
| Membership in networks / associations | BIO Deutschland, BioRiver, European Biopharmaceutical Enterprises (EBE), BEAM-Alliance, Pharma Lizenz Club (plc) Deutschland |
| Date of Incorporation/ Number of Employees |
2006/65 |
Contact :
| Address | Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal |
| Telephone/Telefax | +49 202 317 63 -0/-1177 |
| info@aicuris.com | |
| Web-Address | www.aicuris.com |
| Social media | LinkedIn Twitter |
- AiCuris-Team für den Deutschen Zukunftspreis 2018 nominiert
- Nach FDA-Zulassung: AiCuris-Wirkstoff kommt nach Europa
- AiCuris' Lizenznehmer MSD erhält FDA-Zulassung für PREVYMIS (Letermovir)
- „Die Preisvorstellung von Antibiotika muss und wird sich ändern“
- AiCuris erhält Fast-Track-Status der FDA
- Dem Horror entgegen wirken